NZ630864A - Use of semaphorin-4d binding molecules to promote neurogenesis following stroke - Google Patents
Use of semaphorin-4d binding molecules to promote neurogenesis following strokeInfo
- Publication number
- NZ630864A NZ630864A NZ630864A NZ63086413A NZ630864A NZ 630864 A NZ630864 A NZ 630864A NZ 630864 A NZ630864 A NZ 630864A NZ 63086413 A NZ63086413 A NZ 63086413A NZ 630864 A NZ630864 A NZ 630864A
- Authority
- NZ
- New Zealand
- Prior art keywords
- semaphorin
- binding molecules
- following stroke
- promote neurogenesis
- stroke
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261646119P | 2012-05-11 | 2012-05-11 | |
| US13/842,523 US10494440B2 (en) | 2012-05-11 | 2013-03-15 | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| PCT/US2013/040661 WO2013170221A1 (en) | 2012-05-11 | 2013-05-10 | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630864A true NZ630864A (en) | 2017-03-31 |
Family
ID=49548777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630864A NZ630864A (en) | 2012-05-11 | 2013-05-10 | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10494440B2 (enExample) |
| EP (1) | EP2846831B1 (enExample) |
| JP (1) | JP6218810B2 (enExample) |
| KR (1) | KR102105436B1 (enExample) |
| CN (2) | CN110064054A (enExample) |
| AU (1) | AU2013259192B2 (enExample) |
| BR (1) | BR112014028160B1 (enExample) |
| CA (1) | CA2872928C (enExample) |
| DK (1) | DK2846831T3 (enExample) |
| EA (1) | EA030796B1 (enExample) |
| ES (1) | ES2882881T3 (enExample) |
| IL (1) | IL235603B (enExample) |
| MX (1) | MX358991B (enExample) |
| NZ (1) | NZ630864A (enExample) |
| PT (1) | PT2846831T (enExample) |
| SG (1) | SG11201407416XA (enExample) |
| WO (1) | WO2013170221A1 (enExample) |
| ZA (1) | ZA201501674B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| BR112018071686A2 (pt) | 2016-04-22 | 2019-02-19 | Vaccinex, Inc. | exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| WO2018156509A1 (en) * | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| CN110636858B (zh) | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
| WO2024182357A1 (en) * | 2023-02-28 | 2024-09-06 | Brandeis University | Compositions and methods for the chronic treatment of epilepsy and epileptogenesis |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
| US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| AU776865B2 (en) | 1998-11-10 | 2004-09-23 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| WO2001046384A2 (en) | 1999-12-23 | 2001-06-28 | Cornell Research Foundation, Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| RU2006124743A (ru) | 2003-12-11 | 2008-01-20 | Дженентек, Инк. (Us) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет |
| AU2005209331A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| JP2008504821A (ja) * | 2004-07-01 | 2008-02-21 | バイレクシス コーポレイション | ベクター・パッケージング細胞系列 |
| US7476724B2 (en) | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| EP1871484A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Sema4d in cancer diagnosis, detection and treatment |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| EP2069404B1 (en) | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| WO2009089461A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
| CN102421913A (zh) * | 2009-03-13 | 2012-04-18 | 宾夕法尼亚大学董事会 | Ox40/trail融合蛋白 |
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| US8834883B2 (en) | 2010-06-14 | 2014-09-16 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| US9447191B2 (en) | 2011-05-13 | 2016-09-20 | National University Corporation Tokyo Medical And Dental University | Osteogenesis promoter |
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| WO2018156509A1 (en) * | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
-
2013
- 2013-03-15 US US13/842,523 patent/US10494440B2/en active Active
- 2013-05-10 BR BR112014028160-2A patent/BR112014028160B1/pt active IP Right Grant
- 2013-05-10 JP JP2015511789A patent/JP6218810B2/ja active Active
- 2013-05-10 MX MX2014013676A patent/MX358991B/es active IP Right Grant
- 2013-05-10 CN CN201910064594.5A patent/CN110064054A/zh active Pending
- 2013-05-10 EA EA201492067A patent/EA030796B1/ru not_active IP Right Cessation
- 2013-05-10 CA CA2872928A patent/CA2872928C/en active Active
- 2013-05-10 ES ES13787931T patent/ES2882881T3/es active Active
- 2013-05-10 AU AU2013259192A patent/AU2013259192B2/en not_active Ceased
- 2013-05-10 WO PCT/US2013/040661 patent/WO2013170221A1/en not_active Ceased
- 2013-05-10 DK DK13787931.8T patent/DK2846831T3/da active
- 2013-05-10 PT PT137879318T patent/PT2846831T/pt unknown
- 2013-05-10 KR KR1020147034510A patent/KR102105436B1/ko active Active
- 2013-05-10 NZ NZ630864A patent/NZ630864A/en not_active IP Right Cessation
- 2013-05-10 EP EP13787931.8A patent/EP2846831B1/en active Active
- 2013-05-10 CN CN201380037262.9A patent/CN104619341A/zh active Pending
- 2013-05-10 SG SG11201407416XA patent/SG11201407416XA/en unknown
-
2014
- 2014-11-10 IL IL235603A patent/IL235603B/en active IP Right Grant
-
2015
- 2015-03-11 ZA ZA2015/01674A patent/ZA201501674B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201407416XA (en) | 2015-03-30 |
| CN110064054A (zh) | 2019-07-30 |
| KR20150018555A (ko) | 2015-02-23 |
| CA2872928C (en) | 2021-02-16 |
| BR112014028160B1 (pt) | 2021-01-12 |
| KR102105436B1 (ko) | 2020-04-29 |
| EA201492067A1 (ru) | 2015-05-29 |
| JP2015517502A (ja) | 2015-06-22 |
| ZA201501674B (en) | 2021-06-30 |
| DK2846831T3 (en) | 2021-10-11 |
| CN104619341A (zh) | 2015-05-13 |
| EA030796B1 (ru) | 2018-09-28 |
| IL235603B (en) | 2020-01-30 |
| US10494440B2 (en) | 2019-12-03 |
| ES2882881T3 (es) | 2021-12-03 |
| AU2013259192A1 (en) | 2014-11-27 |
| MX358991B (es) | 2018-08-31 |
| EP2846831A4 (en) | 2015-11-18 |
| IL235603A0 (en) | 2015-01-29 |
| EP2846831A1 (en) | 2015-03-18 |
| EP2846831B1 (en) | 2021-07-07 |
| MX2014013676A (es) | 2015-02-05 |
| AU2013259192B2 (en) | 2018-02-22 |
| PT2846831T (pt) | 2021-08-19 |
| US20130302320A1 (en) | 2013-11-14 |
| WO2013170221A1 (en) | 2013-11-14 |
| CA2872928A1 (en) | 2013-11-14 |
| JP6218810B2 (ja) | 2017-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630864A (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
| PH12013502201A1 (en) | Anti-b7-h3 antibody | |
| MX2021002728A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
| MX2022012089A (es) | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos. | |
| TN2014000120A1 (en) | Cd27l antigen binding proteins | |
| PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
| NZ628314A (en) | Cd47 antibodies and methods of use thereof | |
| PH12015502293A1 (en) | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use | |
| EA201791393A3 (ru) | Антитела к erbb3 и их применение | |
| MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| CA3019531A1 (en) | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer | |
| EP4406593A3 (en) | Use of long-acting glp-1 peptides | |
| MX361242B (es) | Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos. | |
| EA201391585A1 (ru) | Терапевтические нуклеазные композиции и способы | |
| PH12013502568B1 (en) | Anti-psgl-1 antibodies and uses thereof | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| MX368228B (es) | Anticuerpos que se unen específicamente a her2. | |
| MX2021006111A (es) | Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide. | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| WO2013052772A3 (en) | Anti-human sema4a antibodies useful to treat disease | |
| MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
| MX377995B (es) | Moléculas de unión al receptor bag3 para uso como un medicamento. | |
| NZ631118A (en) | Methods for treating nasal polyposis by administering an il-4r antagonist | |
| TN2014000207A1 (en) | Anti il-36r antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 MAY 2020 BY COMPUTER PACKAGES INC Effective date: 20170818 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2021 BY COMPUTER PACKAGES INC Effective date: 20200418 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2022 BY COMPUTER PACKAGES INC Effective date: 20210418 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2023 BY COMPUTER PACKAGES INC Effective date: 20220417 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2024 BY COMPUTER PACKAGES INC Effective date: 20230417 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAY 2025 BY COMPUTER PACKAGES INC Effective date: 20240417 |
|
| LAPS | Patent lapsed |